Download PDF
Z Gastroenterol 2009; 47(7): 671-673
DOI: 10.1055/s-0028-1109174
Kasuistik

© Georg Thieme Verlag KG Stuttgart · New York

Case Report: Extreme CgA Elevation Under PPI Confounding Assessment of Adrenal Mass

Fallbericht: Extreme CgA-Erhöhung unter einem PPI beeinflusst NebennierentumordiagnostikM. W. Wiedmann1 , J. Mössner2 , M. Stumvoll3 , D. Führer3
  • 1Abteilung Innere I, St.-Marien-Krankenhaus Berlin
  • 2Klinik und Poliklinik für Innere Medizin II, Universität Leipzig
  • 3Klinik und Poliklinik für Innere Medizin III, Universität Leipzig
Further Information

Publication History

manuscript received: 19.10.2008

manuscript accepted: 14.1.2009

Publication Date:
15 July 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Bestimmung des Chromogranin-A-Spiegels (CgA-Spiegel) im Blut kann für das Monitoring von neuroendokrinen Tumoren verwendet werden. CgA kann aber auch bei verschiedenen anderen endokrinen und nicht endokrinen Erkrankungen erhöht sein. Wir berichten über einen Patienten mit einem zufällig entdeckten Tumor der linken Nebenniere und einem erhöhten CgA-Spiegel. Die Adrenalektomie bestätigte nicht die vermutete Diagnose eines Phäochromozytoms. Postoperativ fiel ein weiterhin erhöhter CgA-Spiegel auf, der die Vermutung eines weiteren neuroendokrinen Tumors nahe legte, welche trotz einer umfangreichen Diagnostik nicht bestätigt werden konnte. Schließlich wurde entdeckt, dass eine kontinuierliche Protonenpumpenhemmereinnahme wegen einer Refluxösophagitis einen falsch erhöhten CgA-Spiegel verursacht hatte.

Abstract

Measurement of chromogranin A (CgA) level in blood can be used to monitor neuroendocrine tumours. However CgA level may also be elevated in several other endocrine and non-endocrine diseases. Here, we report on a patient with an incidental left-sided adrenal tumour and elevated CgA level. Adrenalectomy did not confirm clinically suspected diagnosis of pheochromocytoma. Postoperative follow-up was remarkable for a persistently elevated CgA level suspecting another neuroendocrine tumour which could not be detected despite extensive investigations. Finally, it was discovered that continuous proton-pump inhibitor administration for gastro-oesophageal reflux disease had caused a falsely elevated CgA level.

Schlüsselwörter

Protonenpumpenhemmer - Chromogranin A - neuroendokriner Tumor

Key words

proton-pump inhibitor - chromogranin A - adrenal incidentaloma

References

  • 1 Ferrari L, Seregni E, Bajetta E. et al . The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.  Anticancer Res. 1999;  19 3415-3427
    Google Scholar
  • 2 Giovanella L, La Rosa S, Ceriani L. et al . Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.  Int J Biol Markers. 1999;  14 160-166
    Google Scholar
  • 3 Nobels F R, Kwekkeboom D J, Bouillon R. et al . Chromogranin A: its clinical value as marker of neuroendocrine tumours.  Eur J Clin Invest. 1998;  28 431-440
    Google Scholar
  • 4 Bajetta E, Ferrari L, Martinetti A. et al . Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.  Cancer. 1999;  86 858-865
    Google Scholar
  • 5 Wu J T, Erickson A J, Tsao K C. et al . Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.  Ann Clin Lab Sci. 2000;  30 175-178
    Google Scholar
  • 6 Nobels F R, Kwekkeboom D J, Coopmans W. et al . Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.  J Clin Endocrinol Metab. 1997;  82 2622-2628
    Google Scholar
  • 7 Berruti A, Dogliotti L, Mosca A. et al . Circulating neuroendocrine markers in patients with prostate carcinoma.  Cancer. 2000;  88 2590-2597
    Google Scholar
  • 8 Drivsholm L, Paloheimo L I, Osterlind. et al . Chromogranin A, a significant prognostic factor in small cell lung cancer.  Br J Cancer. 1999;  81 667-671
    Google Scholar
  • 9 Hachitanda Y, Tsuneyoshi M, Enjoji M. Expression of pan-neuroendocrine proteins in 53 neuroblastic tumors. An immunohistochemical study with neuron-specific enolase, chromogranin, and synaptophysin.  Arch Pathol Lab Med. 1989;  113 381-384
    Google Scholar
  • 10 Igaz P, Mullner K, Hargitai B. et al . Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy.  Clin Endocrinol. 2007;  67 805-806
    Google Scholar
  • 11 White S L, Smith W C, Fisher L F. et al . Quantitation of glandular gastric changes in rats given a proton pump inhibitor for 3 months with emphasis on sampling scheme selection.  Toxicol Pathol. 1998;  26 403-410
    Google Scholar
  • 12 Fossmark R, Jianu C S, Martinsen T C. et al . Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.  Scand J Gastroenterol. 2008;  43 20-24
    Google Scholar
  • 13 Giusti M, Sidoti M, Augeri C. et al . Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man.  Eur J Endocrinol. 2004;  150 299-303
    Google Scholar
  • 14 Sanduleanu S, Stridsberg M, Jonkers D. et al . Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.  Aliment Pharmacol Ther. 1999;  13 145-153
    Google Scholar

PD Dr. Marcus Wolf Wiedmann

Abteilung Innere I, St.-Marien-Krankenhaus Berlin

Gallwitzallee 123 – 143

12249 Berlin

Germany

Phone: ++ 49/30/76 78 32 50

Fax: ++ 49/30/76 78 34 25

Email: wiedmann@marienkrankenhaus-berlin.de

      >